Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 169
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 83
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Hyeok‐Hee Lee, Han Ah Lee, Eun-Jin Kim, et al.
Gut (2023), pp. gutjnl-331003
Closed Access | Times Cited: 80
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
MAFLD predicts cardiovascular disease risk better than MASLD
Ziyan Pan, Gamal Shiha, Gamal Esmat, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1567-1574
Closed Access | Times Cited: 29
Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or both
Xiaodong Zhou, Amedeo Lonardo, Calvin Q. Pan, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. e157-e159
Closed Access | Times Cited: 17
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
Xiaodong Zhou, Seung Up Kim, Terry Cheuk‐Fung Yip, et al.
Gut (2024) Vol. 73, Iss. 11, pp. 1883-1892
Closed Access | Times Cited: 15
MAFLD as part of systemic metabolic dysregulation
Jing Zhao, Lu Liu, Yingying Cao, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 834-847
Closed Access | Times Cited: 14
Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction–Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study
Ki‐Chul Sung, Tae Kyung Yoo, Mi Yeon Lee, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2023) Vol. 43, Iss. 3, pp. 482-491
Open Access | Times Cited: 23
Hepatocytic ballooning in non‐alcoholic steatohepatitis: Dilemmas and future directions
Yangyang Li, Tianlei Zheng, Shu–Yuan Xiao, et al.
Liver International (2023) Vol. 43, Iss. 6, pp. 1170-1182
Open Access | Times Cited: 23
Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis
Nso Nso, Damla Mergen, Mashaal Ikram, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 6, pp. 102569-102569
Closed Access | Times Cited: 11
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Haixiang Zheng, Leonardo A. Sechi, Eliano Pio Navarese, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
High‐Sensitivity C‐Reactive Protein Is Associated With Heart Failure Hospitalization in Patients With Metabolic Dysfunction‐Associated Fatty Liver Disease and Normal Left Ventricular Ejection Fraction Undergoing Coronary Angiography
Xiaodong Zhou, Qin‐Fen Chen, Giovanni Targher, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 10
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Khamis Al-Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 9
Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti
Xie Wei, Jing Gan, Xiaodong Zhou, et al.
Cell Metabolism (2024) Vol. 36, Iss. 6, pp. 1269-1286.e9
Closed Access | Times Cited: 9
Hepatitis E Virus (HEV) Infection Among Immunocompromised Individuals: A Brief Narrative Review
Radostina Alexandrova, Ilia Tsachev, Plamen M. Kirov, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 1021-1040
Open Access | Times Cited: 8
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Robert G. Gish, Jian‐Gao Fan, Zahra Dossaji, et al.
Hepatology International (2024)
Closed Access | Times Cited: 8
Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
Hodaka Yamada, Masashi Yoshida, Shunsuke Funazaki, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 4, pp. 176-176
Open Access | Times Cited: 20
Coexistence of Metabolic Dysfunction‐Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease
Daisuke Miyamori, Marenao Tanaka, Tatsuya Sato, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 14
Open Access | Times Cited: 16
Endoplasmic Reticulum Stress and Its Impact on Adipogenesis: Molecular Mechanisms Implicated
G.D. Kim, Jiyoon Lee, Joohun Ha, et al.
Nutrients (2023) Vol. 15, Iss. 24, pp. 5082-5082
Open Access | Times Cited: 16
From HFpEF to “metabolic (dysfunction)-associated HFpEF”: Time to act
Xiaodong Zhou, Gregory Y.H. Lip, Ming‐Hua Zheng
Science Bulletin (2024) Vol. 69, Iss. 7, pp. 850-852
Closed Access | Times Cited: 7
Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China: A cross-sectional study
Yajun He, Nanfang Yao, Feng Tian, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 3, pp. 102973-102973
Closed Access | Times Cited: 6
Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study
Xiaodong Zhou, Cuifang Xu, Qin‐Fen Chen, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 9, pp. 3684-3695
Closed Access | Times Cited: 6
Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols
Raissa Bulaty Tauil, Paula Takano Golono, Enzo Pereira de Lima, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1354-1354
Open Access | Times Cited: 6
Evolving liver disease insights from NAFLD to MASLD
Xiude Fan, Yongfeng Song, Jiajun Zhao
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 683-686
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top